Press Release

First Line of Treatment Medications to dominate the Tuberculosis Therapeutics Market through 2028

Global Tuberculosis Therapeutics Market to be driven by the increasing prevalence of tuberculosis during the forecast period.


According to TechSci Research report,
Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F, Global Tuberculosis Therapeutics Market is anticipated to grow at an impressive rate in the forecast period, 2024-2028. This can be attributed to the increase in new treatment options for tuberculosis (TB) in the last few years which show promise in improving patient outcomes and reducing the spread of the disease. Additionally, supportive government policies and schemes is further expected to support the growth of global tuberculosis treatment market. One example of a government initiative to develop new TB therapies is the United States' National Institute of Allergy and Infectious Diseases (NIAID) TB Research Unit. This unit is focused on developing new drugs and vaccines for TB, with a particular emphasis on drug-resistant strains of the bacteria. The NIAID TB Research Unit works with researchers from around the world to identify promising drug candidates and test them in clinical trials. Another government initiative is the TB Alliance, a non-profit organization that was created to develop new TB therapies. The TB Alliance is focused on developing drugs that are effective against drug-resistant TB and that can be taken for shorter periods of time than current treatments. The organization has several drugs in clinical trials, including a drug called Pretomanid, which was recently approved by the US Food and Drug Administration (FDA) for the treatment of drug-resistant TB.

However, one of the potential challenges that hampers the growth of global tuberculosis therapeutics market is emergence of drug-resistant strains of the bacteria. This occurs when the bacteria that cause TB mutate and become resistant to the antibiotics used to treat the disease. According to the World Health Organization (WHO), there were an estimated 465,000 cases of multidrug-resistant TB (MDR-TB) in 2020, and an additional 182,000 cases of rifampicin-resistant TB (RR-TB), which is a type of MDR-TB. Treating drug-resistant TB is much more difficult and costly than treating drug-susceptible TB, and there are limited treatment options available, which can lead to poor patient outcomes. Another challenge related to TB therapeutics is the long duration of treatment. Standard treatment for drug-susceptible TB involves taking a combination of antibiotics for six months, while treatment for drug-resistant TB can take up to two years. This long duration of treatment can be a barrier to treatment adherence, which can lead to treatment failure, disease relapse, and the development of drug resistance, thereby slowing down the growth of global tuberculosis therapeutics market in the coming years.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "
Tuberculosis Therapeutics Market.”
 

Global Tuberculosis Therapeutics Market can be segmented by disease type, by therapy, by route of administration, by dosage form, by distribution channel, and by region. Based on disease type, global tuberculosis therapeutics market can be split into active tuberculosis and latent tuberculosis. The active tuberculosis segment dominated the market in 2022 and is expected to continue maintaining its dominance through 2028. This can be attributed to the rising prevalence of active tuberculosis among the population. The latent tuberculosis segment is expected to show the fastest growth rate over the forecast period since in this type the person suffers from the disease without even knowing about it. This form of infection is generally categorized by being present in the body without making the person feel sick.

By therapy, the global tuberculosis therapeutics market can be divided into first line therapy and second line therapy. The first line therapy segment is expected to dominate the global tuberculosis therapeutics market through 2028. This can be ascribed to the development of a large number of first line therapeutic drugs such as isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), streptomycin (SM), and ethambutol (EMB). While second line therapy segment is expected to register the highest growth in the global tuberculosis therapeutics market owing to the increasing instances of drug resistance among the population.

Major companies operating in the Global Tuberculosis Therapeutics Market are:

  • AstraZeneca, Plc.
  • Johnson & Johnson
  • Eli Lilly And Company
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Pfizer Inc.



Download Free Sample Report

Customers can also request for 10% free customization on this report.


“Governments and companies around the world are working to develop new TB therapies to address the significant challenges posed by this disease. These initiatives are focused on developing drugs that are effective against drug-resistant TB, that can be taken for shorter periods of time than current treatments, and that have fewer side effects, this in turn is further expected to support the growth of global tuberculosis therapeutics market in the coming years” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Disease Type (Active Tuberculosis, Latent Tuberculosis), By Therapy (First Line Therapy, Second Line Therapy), By Route of Administration (Oral, Parenteral, Others), By Dosage Form (Tablets, Capsules, Injection, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region and Competition”, has evaluated the future growth potential of Tuberculosis Therapeutics Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global Tuberculosis Therapeutics Market.


Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com

Relevant News